196 related articles for article (PubMed ID: 7927707)
1. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.
Szu SC; Taylor DN; Trofa AC; Clements JD; Shiloach J; Sadoff JC; Bryla DA; Robbins JB
Infect Immun; 1994 Oct; 62(10):4440-4. PubMed ID: 7927707
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
3. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.
Kossaczka Z; Bystricky S; Bryla DA; Shiloach J; Robbins JB; Szu SC
Infect Immun; 1997 Jun; 65(6):2088-93. PubMed ID: 9169736
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
6. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.
Szu SC; Lin KF; Hunt S; Chu C; Thinh ND
Vaccine; 2014 May; 32(22):2618-22. PubMed ID: 24657719
[TBL] [Abstract][Full Text] [Related]
8. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
Singh M; Ganguly NK; Kumar L; Vohra H
Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
[TBL] [Abstract][Full Text] [Related]
9. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.
Szu SC; Stone AL; Robbins JD; Schneerson R; Robbins JB
J Exp Med; 1987 Nov; 166(5):1510-24. PubMed ID: 3681191
[TBL] [Abstract][Full Text] [Related]
10. A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.
Szu SC; Hunt S; Xie G; Robbins JB; Schneerson R; Gupta RK; Zhao Z; Tan X
Vaccine; 2013 Apr; 31(15):1970-4. PubMed ID: 23422143
[TBL] [Abstract][Full Text] [Related]
11. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
13. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
14. Experience with Salmonella typhi Vi capsular polysaccharide vaccine.
Hessel L; Debois H; Fletcher M; Dumas R
Eur J Clin Microbiol Infect Dis; 1999 Sep; 18(9):609-20. PubMed ID: 10534182
[TBL] [Abstract][Full Text] [Related]
15. Development of Vi conjugate - a new generation of typhoid vaccine.
Szu SC
Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
[TBL] [Abstract][Full Text] [Related]
16. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.
Fattom A; Schneerson R; Watson DC; Karakawa WW; Fitzgerald D; Pastan I; Li X; Shiloach J; Bryla DA; Robbins JB
Infect Immun; 1993 Mar; 61(3):1023-32. PubMed ID: 8432585
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.
Szu SC; Li XR; Schneerson R; Vickers JH; Bryla D; Robbins JB
Infect Immun; 1989 Dec; 57(12):3823-7. PubMed ID: 2807549
[TBL] [Abstract][Full Text] [Related]
19. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.
Welch PG; Fattom A; Moore J; Schneerson R; Shiloach J; Bryla DA; Li X; Robbins JB
J Am Soc Nephrol; 1996 Feb; 7(2):247-53. PubMed ID: 8785394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
